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ABSTRACT
Introduction: Aging of the population results
in an increase in senior drivers. Elderly are
frequently treated with benzodiazepines and
antidepressants. The objective of this study was
to determine whether the concurrent use of
benzodiazepines and antidepressants is
associated with motor vehicle accidents
(MVAs) in the elderly.
Methods: This was a nested case–control study
within a cohort of drivers aged 67–84 years
between 1990 and 2000, identified from the
Socie´te´ de l’Assurance Automobile du Que´bec
and the Re´gie de l’Assurance Maladie du Que´bec
databases. First cases of MVAs during follow-up
were matched with up to ten controls from the
cohort. Odds ratios (ORs) for the association
between MVA and the use of benzodiazepines
and antidepressants were estimated using
conditional logistic regression.
Results: The cohort included 373,818 drivers,
with 74,503 MVA cases matched with 744,663
controls. The risk of MVA was higher in current
users of long-acting benzodiazepines [OR 1.23;
95% confidence interval (CI) 1.16–1.29] than in
current users of short-acting benzodiazepines (OR
1.05; 95% CI 1.02–1.08). The risk of MVA was
increased in current users of selective serotonin
reuptake inhibitors (SSRIs; OR 1.13; 95% CI
1.04–1.22), while it was not in current users of
tricyclic antidepressants (TCAs; OR 1.04; 95% CI
0.96–1.14). The highest ORs of MVA were observed
in long-acting benzodiazepines users concurrently
using SSRIs (OR 1.37; 95% CI 1.07–1.77,P value for
interaction = 0.964) or TCAs (OR 1.54; 95% CI
1.21–1.95, P value for interaction = 0.077).
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Conclusion: Use of long-acting benzodiazepines
is associated with an increased risk of MVA in the
elderly, particularly in those concurrently using
SSRIs or TCAs.
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INTRODUCTION
Aging of the population leads to an increase in
senior drivers. It is expected that by the year
2030, drivers older than 65 years of age will be
involved in 1 out of 4 fatal motor vehicles
accidents (MVAs) [1]. Increasing drug exposure
is an important factor linked to an increase in
the risk of MVA in the elderly [2]. Psychotropic
drugs have particularly been under scrutiny for
the recent years, with special focus on
benzodiazepines and antidepressants [3].
Benzodiazepines have been identified with the
most consistent increase in risk of MVA in the
elderly [4–8]. Results of large case–control
studies suggested that long-acting
benzodiazepines are associated with greater
risk of MVA than short-acting benzodiazepines
in elderly drivers [5, 6], similarly to what has
been previously demonstrated in the younger
population. Antidepressant use has also been
associated with an increased risk of MVA [4, 7,
9–12]. The increase in risk has been initially
observed for tricyclic antidepressants (TCAs) [4].
Further studies confirmed this increase in risk
for newer antidepressants, including selective
serotonin reuptake inhibitors (SSRIs) [10–12].
Benzodiazepines and antidepressants are
often indicated to treat depression or anxiety
disorders [13, 14], and antidepressant use has
been on the rise among the elderly during the
last decade [15, 16]. From a pharmacological
perspective, it is plausible that the concurrent
use of both benzodiazepines and antidepressants
may increase the risk of MVA. Antidepressants
have the potential to aggravate psychomotor
impairment and sedation induced by
benzodiazepines through pharmacodynamics
interactions or pharmacokinetic interactions
[17]. However, few studies have focused on
concomitant use of benzodiazepines and
antidepressants and driving abilities in the
elderly [4, 11]. Ray et al. [4] showed a 110%
increase in MVAs in older drivers taking both
benzodiazepines and TCAs, that was not
significantly different from users of
benzodiazepines or TCAs alone. On the other
hand, Rapoport et al. [11] reported that in older
drivers using antidepressants, concomitant use
of benzodiazepines was associated with a 23%
increase of at-fault MVAs, compared to
antidepressants alone.
Given the limited safety data on the
combinations of the aforementioned drugs, we
conducted a large population-based study to
determine whether the concurrent use of
benzodiazepines and antidepressants is
associated with MVAs in the elderly.
METHODS
Data Source
The study was conducted using the Socie´te´ de
l’Assurance Automobile du Que´bec (SAAQ) and
the Re´gie de l’Assurance Maladie du Que´bec
(RAMQ) databases, from the province of
Quebec, Canada.
The SAAQ databases record information
about drivers, vehicles, and accidents, and
have been initially designed for administrative
purposes. A specific file contains MVA report
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forms that are completed both for crashes
involving injury and those with material
damage only. They contain information
regarding the accident (date, time, location,
and type of the accident, weather and road
conditions, number and type of vehicles
involved, estimated amount of vehicle and
property damage), as well as persons involved
(vehicle occupied, position in car, seatbelt use,
nature of injuries, health care number, and
hospital to which injured were transported).
Police officers are required to complete this
report for accidents involving physical harm,
where material damages exceed $1,000 in value,
or where a crime or offense was committed.
The RAMQ databases comprise data on all
residents of the province of Quebec covered by
the provincial health insurance plan ([7
million people). These databases capture all
physician visits, procedures, hospitalizations,
patient demographics, and pharmacy claims
for prescription medications. Variables
contained within the prescription database
include drug name, date of dispensing,
number of units administered, dose per unit,
and duration of prescribed treatment.
The linkage between SAAQ databases and
RAMQ databases was performed using either the
social insurance number or a probability match
that used the name, address, and date of birth.
The linkage between SAAQ and RAMQ
databases has already been efficiently used in
previous studies [5, 12, 18].
Design
We conducted a nested case–control study
within a cohort of drivers between the ages
of 67 and 84 years in the study period June 1,
1990 to May 31, 2000. We thus extended by
7 years the study period of a previous cohort
study conducted in the same databases [5]. All
subjects had to have a valid driver’s license.
The cohort was restricted to subjects using a
RAMQ service (medical or pharmaceutical) at
least once per year during their follow-up, to
ensure that all cohort subjects were residing in
the province of Quebec during the whole
study period. Cohort entry was defined as
June 1, 1990, the date of a subject’s 67th
birthday, or the day that a valid driver’s license
was issued, whichever occurred last. All
subjects were followed up until May 31,
2000, their 84th birthday, expiry of their
driver’s license, or death, whichever occurred
first.
Cases and Controls
Cases were all first MVAs during follow-up,
including injurious accidents and accidents
with property damage only. Cases were
matched to up to ten controls on sex, age at
cohort entry, and duration of follow-up.
Controls were randomly selected from the risk
set made up of all members of the cohort who
were at risk for the outcome at the time of the
index date (date of accident). In accord with
basic principles, subjects may have been
selected more than once, but on different
days, of their follow-up.
Exposure
Exposure to medications was assessed in the
2 years prior to the index date using both
information pertaining to the date a
medication was dispensed, and duration of
treatment as recorded in the medication
prescription file of the RAMQ databases. The
use of medications was classified into four
mutually exclusives categories: (1) new use, if
the medication prescription was issued in the
30 days before index date only, and supply
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lasted at least until the index date; (2) current,
not new use, if the medication prescription was
issued earlier than 30 days before index date
and supply lasted at least until the index date;
(3) past use, consisting of other prescription
patterns; and (4) no use, which was the
reference category for all analyses. For
secondary analyses with small group sizes, new
use and current, not new use were combined
into a single current use category.
Antidepressants were studied as an
all-inclusive drug category, and then according
to the three following classes: TCAs
(amitriptyline, amoxapine, clomipramine,
desipramine, doxepin, imipramine, maprotiline,
nortriptyline, protriptyline, trimipramine), SSRIs
(citalopram, fluoxetine, fluvoxamine, paroxetine,
sertraline) and other antidepressants (bupropion,
moclobemide, nefazodone, phenelzine,
tranylcypromine, trazodone, venlafaxine).
Benzodiazepines were studied as an all-inclusive
drug category, and then classified as long-acting
benzodiazepines (chlordiazepoxide, clobazam,
clonazepam, clorazepate, diazepam, flurazepam,
and nitrazepam) and short-acting
benzodiazepines (alprazolam, bromazepam,
lorazepam, midazolam, oxazepam, temazepam,
and triazolam).
Sensitivity Analysis
The first sensitivity analysis restricted the
outcome definition to injurious MVAs only, to
assess the risk of drug use on the risk of these
serious events. In a second sensitivity analysis,
the exposure duration associated with the last
prescription for an antidepressant or a
benzodiazepine was extended by 30 days, to
account for the potential sustained effects of
drug use occurring as a result of their
pharmacokinetic properties (e.g., the
elimination half-life) of these drugs.
Statistical Analysis
Conditional logistic regression models were used
to compute odds ratios (ORs) with their 95%
confidence interval (CI) for associations between
the use of benzodiazepines and antidepressants
and the MVAs, which, for the time-matched
nested case–control method used here, provides
unbiased estimates of the rate ratio and their 95%
CI [19]. In addition to matching on sex, age at
cohort entry, and duration of follow-up, potential
confounding was addressed by adjusting the
models for accidents which occurred during the
five-year period prior to cohort entry, the number
of general practice visits, the number of drug
categories concomitantly used in the year prior to
index date between cardiovascular drugs, glucose-
lowering drugs, anti-infective agents and
bronchodilators (as a proxy of comorbidity), the
number of overall distinct drugs dispensed during
the year prior to index date, and the use of other
central nervous system drugs (anti-Parkinson
drugs, opioids, anticonvulsants, other) in the
90 days prior to index date.
The concurrent use of benzodiazepines and
antidepressants was estimated using interaction
terms for each of the combinations of
benzodiazepines and antidepressants, and
presented by stratified analyses according to
type of benzodiazepines, antidepressants, and
type of use [none, past, current (new and
current not new, as stated above)).
All computations were performed using the
SAS software version 9.3 (SAS Institute Inc.,
Cary, NC, USA).
Compliance with Ethics Guidelines
The study protocol was approved by the
Research Ethics Committee of the Jewish
General Hospital, Montreal, Canada. All data
used in this study were anonymized.
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RESULTS
Characteristics of Cases and Controls
From the study cohort of 373,818 eligible
drivers aged 67–84 years, 74,503 cases of first
MVAs were identified, including 12,534 causing
injuries (16.8%) and 441 causing fatalities
(0.6%). These cases were matched to 744,663
controls (Fig. 1). Table 1 presents the general
characteristics and the distribution of
comorbidities and comedications among cases
and controls. Cases were more likely to have
had a MVA in the 5 years preceding cohort
entry than controls. Cases were also more likely
to have more general practice consultations
before index date, and were exposed to more
drugs than controls.
MVAs and Use of Benzodiazepines
or Antidepressants
Table 2 presents the crude and adjusted OR for
MVA associated with the use of benzodiazepines
Fig. 1 Flowchart of study subjects. RAMQ Re´gie de l’Assurance Maladie du Que´bec
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Table 1 Characteristics of motor vehicle accident cases and matched controls
Characteristics Cases (74,503) Controls (744,663)
Age, n (%)
67–69 years 23,764 (31.9) 237,640 (31.9)
70–72 years 18,976 (25.5) 189,760 (25.5)
73–75 years 13,270 (17.8) 132,700 (17.8)
[75 years 18,493 (24.8) 184,563 (24.8)
Follow-up, mean (SD) years 3.05 (2.4) 3.05 (2.4)
Male, n (%) 60,567 (81.3) 605,467 (81.3)
Accidents in the 5 years prior cohort entry, n (%)
Causing a fatality 51 (0.07) 394 (0.05)
Causing severe injuries 633 (0.8) 4,512 (0.6)
Causing light injuries 4,539 (6.1) 32,143 (4.3)
Causing\$500 material damage 4,820 (6.5) 31,450 (4.2)
Causing C$500 material damage 17,771 (23.8) 126,721 (17.0)
Number of general practice visits, n (%)a
0 7,271 (9.8) 80,445 (10.8)
1–3 24,114 (32.4) 253,198 (34.0)
4–9 29,689 (39.8) 289,772 (38.9)
C10 13,429 (18.0) 121,248 (16.3)
Number of drug categories among cardiovascular drugs, glucose-lowering drugs, anti-infective agents and bronchodilators, n (%)a
0 25,242 (33.9) 257,260 (34.5)
1 32,368 (43.4) 328,476 (44.1)
2 13,324 (17.9) 127,118 (17.1)
3 3,365 (4.5) 30,139 (4.0)
4 204 (0.3) 1,670 (0.2)
Number of distinct drugs, n (%)a
0–2 16,961 (22.8) 180,344 (24.2)
3–5 22,707 (30.5) 233,738 (31.4)
6–9 20,788 (27.9) 202,128 (27.1)
10–13 9,048 (12.1) 84,510 (11.3)
[13 4,999 (6.7) 43,943 (5.9)
Use of central nervous system drugs, n (%)b
Anticonvulsants 891 (1.2) 8,151 (1.1)
Anti-Parkinson drugs 373 (0.5) 4,067 (0.5)
Opioid 494 (0.7) 5,646 (0.8)
Other central nervous system drugs 559 (0.8) 5,192 (0.7)
a During the year prior to the index date
b Dispensed during the 90-day period prior to the index date
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or antidepressants. The risk of MVA was higher
in current, not new users of long-acting
benzodiazepines (adjusted OR 1.23; 95% CI
1.16–1.29) than short-acting benzodiazepines
(adjusted OR 1.05; 95% CI 1.02–1.08). The risk
of MVA was increased in SSRIs users (new users:
adjusted OR 1.25; 95% CI 1.00–1.55, current,
not new users: adjusted OR 1.13; 95% CI
1.04–1.22), while there was no observed
increased risk among TCAs users (new users:
adjusted OR 0.93; 95% CI 0.67–1.28, current,
not new users: adjusted OR 1.04; 95% CI
0.96–1.14).
MVAs and Concurrent Use
of Benzodiazepines and Antidepressants
Tables 3 and 4 present the crude and adjusted
estimates of effect for the risk of MVA associated
with concurrent use of benzodiazepines and
antidepressants. Among users of antidepressants,
the risk of MVA was increased in concurrent users
of long-actingbenzodiazepines (adjustedOR1.43;
95% CI 1.21–1.69) and in concurrent users of
short-acting benzodiazepines (adjusted OR 1.19;
95% CI 1.06–1.34), with no statistically
significant interaction (P values for
interaction = 0.325 and 0.393, respectively;
Table 3). Among users of long-acting
benzodiazepines, there was an increased risk of
MVA in both concurrent users of SSRIs (adjusted
OR 1.37; 95% CI 1.07–1.77, P value for
interaction = 0.964) and concurrent users of
TCAs (adjusted OR 1.54; 95% CI 1.21–1.95,
P value for interaction = 0.077; Table 4).
Sensitivity Analysis
Restricting the analysis to injurious MVAs
identified 18,403 cases that were matched to
183,933 controls, and led to similar results
[Tables S1, S2, S3, and S4 in the electronic
supplementary material (ESM)]. Extending the
last benzodiazepine or antidepressant exposure
period by an additional 30 days resulted in little
modification of the estimates (Tables S5, S6, and
S7 in the ESM).
DISCUSSION
We investigated the association between the
concurrent use of benzodiazepines and
antidepressants and the risk of MVA in the
elderly in this large population-based study.
Our results reaffirm that the increased risk
associated with the current use of long-acting
benzodiazepines is greater than current use of
short-acting benzodiazepines (23 and 5%
increased risk, respectively). In concurrent
users of benzodiazepines and antidepressants,
the increased risk of MVA was the highest
in concurrent users of long-acting
benzodiazepines and SSRIs (37% increased risk)
or TCAs (54% increased risk), although no
statistically significant interactions were found.
The study results are concordant with a
previous study conducted in the same
databases 20 years ago reporting a 26%
increased risk for elderly continuously using
long-acting benzodiazepines, while no
significant increased risk was observed in users
of short-acting benzodiazepines [5]. Neutel [6]
also reported that the increased risk of MVA
observed in drivers aged over 60 years was the
highest in users of long-acting benzodiazepines.
Conversely, two other epidemiological studies
that were limited by statistical power did not
observe a significant association between use of
long-acting benzodiazepines and MVAs in
elderly drivers [9, 20]. Of note, although the
increase in risk of MVA is deemed highest in the
first days of use among users of benzodiazepines
[5, 6], we observed no significant increase in risk
in new users of benzodiazepines. We have no
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None 68,619 (92.1) 693,839 (93.2) 1.00 (reference) 1.00 (reference)
New 87 (0.1) 807 (0.1) 1.09 (0.88–1.36) 1.03 (0.83–1.29)
Current, not new 1,718 (2.3) 13,463 (1.8) 1.29 (1.23–1.36) 1.23 (1.16–1.29)
Past only 4,079 (5.5) 36,554 (4.9) 1.13 (1.09–1.17) 1.07 (1.04–1.11)
Short-acting
None 58,630 (78.7) 597,030 (80.2) 1.00 (reference) 1.00 (reference)
New 138 (0.2) 1,480 (0.20) 0.96 (0.80–1.14) 0.93 (0.78–1.10)
Current, not new 5,123 (6.8) 47,502 (6.4) 1.11 (1.07–1.14) 1.05 (1.02–1.08)
Past only 10,612 (14.2) 98,651 (13.2) 1.10 (1.08–1.13) 1.05 (1.03–1.08)
Antidepressants
Selective serotonin reuptake inhibitors
None 72,173 (96.9) 724,276 (97.3) 1.00 (reference) 1.00 (reference)
New 93 (0.1) 690 (0.09) 1.35 (1.09–1.68) 1.25 (1.00–1.55)
Current, not new 759 (1.0) 6,166 (0.8) 1.24 (1.15–1.33) 1.13 (1.04–1.22)
Past only 1,478 (2.0) 13,531 (1.8) 1.10 (1.04–1.16) 1.00 (0.95–1.06)
Tricyclic antidepressants
None 72,264 (97.0) 724,937 (97.3) 1.00 (reference) 1.00 (reference)
New 41 (0.06) 418 (0.06) 0.98 (0.71–1.36) 0.93 (0.67–1.28)
Current, not new 552 (0.7) 4,855 (0.6) 1.14 (1.05–1.25) 1.04 (0.96–1.14)
Past only 1,646 (2.2) 14,453 (1.9) 1.14 (1.09–1.20) 1.05 (0.99–1.10)
Other antidepressants
None 73,705 (98.9) 738,034 (99.1) 1.00 (reference) 1.00 (reference)
New 28 (0.04) 233 (0.03) 1.20 (0.81–1.78) 1.10 (0.74–1.63)
Current, not new 209 (0.3) 1,722 (0.2) 1.22 (1.05–1.41) 1.09 (0.94–1.26)
Past only 561 (0.7) 4,674 (0.6) 1.20 (1.10–1.31) 1.07 (0.98–1.17)
Values are numbers (percentages) unless stated otherwise
a Adjusted for variables in Table 1
CI conﬁdence interval
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specific explanation for this discrepancy, which
may be driven by unmeasured confounders.
Regarding the risk associated with the use of
antidepressants, our results reaffirm the
increased risk previously observed with SSRIs
[10–12]. The non-significant OR observed in our
study associated with TCAs use is discordant
with the increased risk observed 20 years ago
[4], but concordant with a more recent study
[11]. This may either be explained by a temporal






Odds ratio (95% CI)
Crude Adjusteda
Benzodiazepines (any) and antidepressants
Neither 52,819 (70.9) 544,069 (73.1) 1.00 (reference) 1.00 (reference)
Current benzodiazepine, current antidepressantb 442 (0.6) 3,302 (0.4) 1.39 (1.26–1.54) 1.28 (1.16–1.42)
Current benzodiazepine, no antidepressantb 5,832 (7.8) 53,675 (7.2) 1.13 (1.10–1.16) 1.08 (1.05–1.12)
No benzodiazepine, current antidepressantb 718 (1.0) 6,712 (0.9) 1.10 (1.02–1.19) 1.04 (0.96–1.13)
Other combinations 14,692 (19.7) 136,905 (18.4) 1.11 (1.09–1.13) 1.07 (1.05–1.09)
Long-acting benzodiazepines and antidepressants
Neither 64,971 (87.2) 660,856 (88.7) 1.00 (reference) 1.00 (reference)
Current long-acting benzodiazepines, current
antidepressantb
163 (0.2) 1,068 (0.1) 1.56 (1.32–1.84) 1.43 (1.21–1.69)
Current long-acting benzodiazepines, no
antidepressantb
1,469 (2.0) 11,896 (1.6) 1.26 (1.19–1.33) 1.21 (1.14–1.28)
No long-acting benzodiazepine, current
antidepressantb
1,230 (1.6) 10,923 (1.5) 1.15 (1.08–1.22) 1.08 (1.01–1.14)
Other combinations 6,670 (8.9) 59,920 (8.0) 1.13 (1.10–1.16) 1.08 (1.05–1.11)
Short-acting benzodiazepines and antidepressants
Neither 64,971 (87.2) 660,856 (88.7) 1.00 (reference) 1.00 (reference)
Current short-acting benzodiazepines, current
antidepressantb
304 (0.4) 2,373 (0.3) 1.31 (1.16–1.47) 1.19 (1.06–1.34)
Current short-acting benzodiazepines, no
antidepressantb
523 (0.7) 4,294 (0.6) 1.24 (1.13–1.36) 1.10 (0.99–1.22)
No short-acting benzodiazepines, current
antidepressantb
911 (1.2) 8,183 (1.1) 1.13 (1.06–1.21) 1.06 (0.99–1.14)
Other combinations 7,794 (10.5) 68,957 (9.3) 1.15 (1.12–1.18) 1.06 (1.02–1.11)
Values are numbers (percentages) unless stated otherwise
a Adjusted for variables in Table 1
b New users and current, not new users were grouped in current users, because of small group size
CI conﬁdence interval
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trend in prescribing which have favored SSRIs
over TCAs in recent years, or possibly by an
increased propensity in patients using TCAs (as
opposed to SSRIs) to refrain from driving.
In concurrent users of antidepressants and
benzodiazepines, the increased risk of MVA
was the highest in concurrent users of long-
acting benzodiazepines and TCAs (54%
increased risk), with the interaction almost
attaining statistical significance. This result
suggests that the 23% increase of at-fault
MVAs previously observed in concurrent users
Table 4 Odds ratios of motor vehicle accidents (any) associated with exposure to concurrent use of long-acting





Odds ratio (95% CI)
Crude Adjusteda
Long-acting benzodiazepines and SSRIs (any)
Neither 66,824 (89.7) 677,643 (91.0) 1.00 (reference) 1.00 (reference)
Current long-acting benzodiazepines, current
SSRIb
69 (0.09) 456 (0.06) 1.54 (1.20–1.98) 1.37 (1.07–1.77)
Current long-acting benzodiazepines, no SSRIb 1,656 (2.2) 13,194 (1.8) 1.27 (1.21–1.34) 1.22 (1.15–1.28)
No long-acting benzodiazepine, current SSRIb 638 (0.9) 5,493 (0.7) 1.18 (1.08–1.28) 1.10 (1.01–1.19)
Other combinations 5,316 (7.1) 47,877 (6.4) 1.13 (1.09–1.16) 1.07 (1.03–1.10)
Long-acting benzodiazepines and TCAs (any)
Neither 66,937 (89.8) 678,609 (91.1) 1.00 (reference) 1.00 (reference)
Current long-acting benzodiazepines, current
TCAb
79 (0.1) 489 (0.07) 1.65 (1.30–2.09) 1.54 (1.21–1.95)
Current long-acting benzodiazepines, no TCAb 1,608 (2.2) 12,916 (1.7) 1.26 (1.20–1.33) 1.21 (1.14–1.27)
No long-acting benzodiazepine, current TCAb 435 (0.6) 4,036 (0.5) 1.10 (0.99–1.21) 1.03 (0.93–1.14)
Other combinations 5,444 (7.3) 48,613 (6.5) 1.14 (1.10–1.17) 1.08 (1.05–1.11)
Long-acting BDZ and other antidepressants
Neither 68,032 (91.3) 688,741 (92.5) 1.00 (reference) 1.00 (reference)
Current long-acting benzodiazepines, current
other antidepressantb
24 (0.03) 145 (0.02) 1.68 (1.09–2.59) 1.49 (0.97–2.31)
Current long-acting benzodiazepines, no other
antidepressantb
1,739 (2.3) 13,841 (1.9) 1.27 (1.21–1.34) 1.21 (1.15–1.28)
No long-acting benzodiazepine, current other
antidepressantb
180 (0.2) 1,511 (0.2) 1.21 (1.03–1.41) 1.11 (0.95–1.29)
Other combinations 4,528 (6.1) 40,425 (5.4) 1.14 (1.10–1.17) 1.07 (1.04–1.11)
Values are numbers (percentages) unless stated otherwise
a Adjusted for variables in Table 1
b New users and current, not new users were grouped in current users, because of small group size
CI conﬁdence interval, SSRI selective serotonin reuptake inhibitors, TCA tricyclic antidepressants
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of both TCAs and benzodiazepines, compared
to those observed in users of TCAs alone [11]
may be largely attributable to long-acting
benzodiazepine use. Our data indicate a
potential for synergistic interaction between
TCAs and long-acting benzodiazepines,
through increases in sedation and
psychomotor impairment, which would need
to be confirmed in further studies.
Numerous experimental studies have
assessed the impact of the use of
benzodiazepines or antidepressants on
psychomotor and driving skills [21]. Among
these, few have focused on elderly subjects [22–
24]. Although these studies were limited by
small sample sizes, their results suggested that
the elderly may not be more susceptible when
compared with younger individuals to
psychomotor and driving impairment induced
by benzodiazepines [23, 24]. In one study, for
example, no acute driving impairment was
observed in 12 elderly subjects administrated
50 mg of imipramine, whereas a significant
impairment was observed in 12 younger
subjects [22]. In addition, only one study
assessed the impact of concomitant use of
antidepressants or benzodiazepines on
psychomotor skills, but focused on young
subjects only [25]. In 24 healthy young
subjects randomly assigned to TCAs and
diazepam (alone or in combination) or
placebo, a significant impairment was
observed in subjects administered
combinations of TCAs and diazepam for up to
6 h, whereas when these drugs were
administered alone there were no such effects
[25]. To our knowledge, no similar study has
been conducted in elderly subjects, and no
study has assessed the psychomotor abilities or
driving abilities of subjects chronically exposed
to these drug combinations.
This study has a number of strengths. First,
the use of the linked RAMQ and SAAQ databases
enabled us to constitute a large population-
based cohort of elderly drivers, and to account
for important potential confounders, such as
comorbidity or use of other central nervous
system drugs. In addition, results of our
sensitivity analyses produced risk estimates
consistent with our primary analyses results.
This study does have limitations. First,
RAMQ databases record pharmacy claims for
prescription medications, and it is uncertain
whether patients adhered to their prescribed
treatment. Moreover, no information on the
timing of drug intake is available. Potential
differences for morning or bedtime intake of
benzodiazepines or TCAs (if used for sleep
disorders) could thus not be assessed. In
addition, the period of time immediately
following either the introduction to or a
change of dosage in benzodiazepines or
antidepressants is of special interest among
elderly patients. It has been shown that there
exists a 50% increased risk of injurious MVAs
within the 7 days following the initiation of
long-acting benzodiazepines [5]. Due to
insufficient power, however, we were unable
to assess the possibility of risk modification for
new users of benzodiazepines in current users of
antidepressant (and vice versa). Results of this
study should also be interpreted with caution,
since confounding by indication or channeling
cannot be ruled out: it is uncertain if the
observed increased risk in elderly drivers
treated with combinations of antidepressants
and benzodiazepines is directly related to their
pharmacological effects, or whether this
increased risk is related to more severe
underlying depression/anxiety disorder or
unmeasured patients’ characteristics. Finally,
given the observational nature of the study,
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the potential for residual confounding needs to
be considered.
CONCLUSIONS
Assessment of MVA risk in the elderly is
challenging. We confirmed that use of long-
acting benzodiazepines or SSRIs may be
associated with an increased risk of both
injurious and non-injurious MVA in the
elderly. An increase in risk was also observed
in drivers concurrently exposed to
benzodiazepines and antidepressant (whether
SSRIs or TCAs). Older patients should be
cautioned about these risks, and advised
regarding their driving activity while under
treatment with long-acting benzodiazepines
and SSRIs or TCAs.
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